DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wen, X.
Right arrow Articles by Neuvonen, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wen, X.
Right arrow Articles by Neuvonen, P. J.

Vol. 30, Issue 6, 631-635, June 2002

Trimethoprim and Sulfamethoxazole are Selective Inhibitors of CYP2C8 and CYP2C9, Respectively

Xia Wen, Jun-Sheng Wang, Janne T. Backman, Jouko Laitila, and Pertti J. Neuvonen

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

To evaluate the inhibitory effects of trimethoprim and sulfamethoxazole on cytochrome P450 (P450) isoforms, selective marker reactions for CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 were examined in human liver microsomes and recombinant CYP2C8 and CYP2C9. The in vivo drug interactions of trimethoprim and sulfamethoxazole were predicted in vitro using [I]/([I] + Ki) values. With concentrations ranging from 5 to 100 µM, trimethoprim exhibited a selective inhibitory effect on CYP2C8-mediated paclitaxel 6alpha -hydroxylation in human liver microsomes and recombinant CYP2C8, with apparent IC50 (Ki) values of 54 µM (32 µM) and 75 µM, respectively. With concentrations ranging from 50 to 500 µM, sulfamethoxazole was a selective inhibitor of CYP2C9-mediated tolbutamide hydroxylation in human liver microsomes and recombinant CYP2C9, with apparent IC50 (Ki) values of 544 µM (271 µM) and 456 µM, respectively. With concentrations higher than 100 µM trimethoprim and 500 µM sulfamethoxazole, both drugs lost their selectivity for the P450 isoforms. Based on estimated total hepatic concentrations (or free plasma concentrations) of the drugs and the scaling model, one would expect in vivo in humans 80% (26%) and 13% (24%) inhibition of the metabolic clearance of CYP2C8 and CYP2C9 substrates by trimethoprim and sulfamethoxazole, respectively. In conclusion, trimethoprim and sulfamethoxazole can be used as selective inhibitors of CYP2C8 and CYP2C9 in in vitro studies. In humans, trimethoprim and sulfamethoxazole may inhibit the activities of CYP2C8 and CYP2C9, respectively.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 PsychosomaticsHome page
J. R. Oesterheld, K. Cozza, and N. B. Sandson
Oral Contraceptives
Psychosomatics, April 1, 2008; 49(2): 168 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Tornio, M. Niemi, P. J. Neuvonen, and J. T. Backman
Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone
Drug Metab. Dispos., January 1, 2008; 36(1): 73 - 80.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R.-J. Sanders, R. Ofman, M. Duran, S. Kemp, and R. J. A. Wanders
{omega}-Oxidation of Very Long-chain Fatty Acids in Human Liver Microsomes: IMPLICATIONS FOR X-LINKED ADRENOLEUKODYSTROPHY
J. Biol. Chem., May 12, 2006; 281(19): 13180 - 13187.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Chang, D. E. Moody, and E. F. McCance-Katz
NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE
Drug Metab. Dispos., March 1, 2006; 34(3): 440 - 448.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
K.-A. Kim, P.-W. Park, H.-K. Kim, J.-M. Ha, and J.-Y. Park
Effect of Quercetin on the Pharmacokinetics of Rosiglitazone, a CYP2C8 Substrate, in Healthy Subjects
J. Clin. Pharmacol., August 1, 2005; 45(8): 941 - 946.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Picard, T. Cresteil, N. Djebli, and P. Marquet
IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS
Drug Metab. Dispos., May 1, 2005; 33(5): 689 - 695.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R.-J. Sanders, R. Ofman, F. Valianpour, S. Kemp, and R. J. A. Wanders
Evidence for two enzymatic pathways for {omega}-oxidation of docosanoic acid in rat liver microsomes
J. Lipid Res., May 1, 2005; 46(5): 1001 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. L. Walsky, E. A. Gaman, and R. S. Obach
Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8
J. Clin. Pharmacol., January 1, 2005; 45(1): 68 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J.-S. Wang and C. L. DeVane
INVOLVEMENT OF CYP3A4, CYP2C8, AND CYP2D6 IN THE METABOLISM OF (R)- AND (S)-METHADONE IN VITRO
Drug Metab. Dispos., June 1, 2003; 31(6): 742 - 747.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. N. Juurlink, M. Mamdani, A. Kopp, A. Laupacis, and D. A. Redelmeier
Drug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity
JAMA, April 2, 2003; 289(13): 1652 - 1658.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J.-S. Wang, M. Neuvonen, X. Wen, J. T. Backman, and P. J. Neuvonen
Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes
Drug Metab. Dispos., December 1, 2002; 30(12): 1352 - 1356.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.